Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score a...
November 01 2018 - 7:00AM
Planning Phase II Trial
Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec
Biomedical Inc. (CSE: BTH) (CNSX: BTH)
(FRANKFURT: BTI) (OTCQB: BTHCF) (the
“
Company” or “Nash Pharma”) is pleased to announce
that its lead compound for non-alcoholic steatohepatitis (“NASH”)
NP-160 showed positive results in a recently completed study
investigating its therapeutic effects in the widely used STAM™
mouse model from SMC Laboratories. NP-160 is one of a number of
already approved compounds that Nash Pharma has been screening for
new therapeutic uses as part of its drug repurposing strategy.
Data from this study demonstrated statistically
significant improvements in several key measures relevant to the
development and progression of NASH including:
- A 2.0 reduction in the NAFLD/NAS score vs controls
(p<0.05)
- A 42.0% reduction in fibrosis as measured by Sirius red
staining (p<0.01)
- In the same study, Telmisartan (a well accepted control in NASH
studies) significantly reduced the NAS score by 2.0 points
(p<0.05) and reduced fibrosis by 19.7% (not statistically
significant)
- No negative side effects were observed.
“The NASH market segment represents an enormous
unmet medical need globally and there is a particular interest in
compounds exhibiting anti-fibrotic activity,” said Christopher J.
Moreau CEO of Nash Pharma. “We plan to present our preclinical in
vivo NASH results at the upcoming 2nd Global NASH Congress, in
February 2019 in London, UK and have now begun preparations to
start a Phase IIa study for our repurposed lead candidate NP-160 in
2019.”
About NASH/NFLD
According to a new report published by Allied
Market Research, “Global Opportunity Analysis and Industry
Forecast, 2021-2025," the global NASH market was valued at $1.17
Billion in 2017, and is expected to reach $21.4 Billion by 2025,
growing at a CAGR of 58.4% from 2021 to 2025. Currently, there are
no US FDA approved treatments for NAFLD or NASH.
About Nash Pharmaceuticals
Inc.
Nash Pharmaceuticals Inc. is a wholly owned
subsidiary of Breathtec Biomedical Inc. Nash is a clinical
stage pharmaceutical development company focused on drug
repurposing in the areas of non–alcoholic steatohepatitis (NASH),
chronic kidney disease (CKD) and inflammatory bowel disease (IBD).
Drug repurposing is the process of discovering new therapeutic
uses for existing drugs.
For more information,
visit https://nashpharmaceuticals.com/.
CONTACT INFORMATION
Christopher J. Moreau CEONash Pharmaceuticals Inc.604.398.4175
ext 701info@breathtechbiomedical.com
investors@breathtecbiomedical.com www.breathtecbiomedical.com
The CSE does not accept responsibility
for the adequacy or accuracy of this release.
Neither the Canadian Securities Exchange nor its Market
Regulator (as that term is defined in the policies of the Canadian
Securities Exchange) accepts responsibility for the adequacy or
accuracy of this release. The Canadian Securities Exchange has not
in any way passed upon the merits of the proposed transaction and
has neither approved nor disapproved the contents of this press
release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities
Exchange has reviewed nor accepts responsibility for the adequacy
or accuracy of the content of this news release. This news release
contains forward-looking statements relating to product
development, licensing, commercialization and regulatory compliance
issues and other statements that are not historical facts.
Forward-looking statements are often identified by terms such as
“will”, “may”, “should”, “anticipate”, “expects” and similar
expressions. All statements other than statements of historical
fact, included in this release are forward-looking statements that
involve risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and actual results and
future events could differ materially from those anticipated in
such statements. Important factors that could cause actual results
to differ materially from the Company’s expectations include the
failure to satisfy the conditions of the relevant securities
exchange(s) and other risks detailed from time to time in the
filings made by the Company with securities regulations. The reader
is cautioned that assumptions used in the preparation of any
forward-looking information may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from
those predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the
control of the Company. The reader is cautioned not to place undue
reliance on any forward-looking information. Such information,
although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may
differ materially from those anticipated. Forward-looking
statements contained in this news release are expressly qualified
by this cautionary statement. The forward-looking statements
contained in this news release are made as of the date of this news
release and the Company will update or revise publicly any of the
included forward-looking statements as expressly required by
applicable law.
Breathtec BioMedical Inc. (CSE:BTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Breathtec BioMedical Inc. (CSE:BTH)
Historical Stock Chart
From Apr 2023 to Apr 2024